"People can lose more fat." Retatrutide: Next-gen obesity drug helps patients lose 28% of body weight In a phase-three trial by Eli Lilly, patients on the highest dose lost an average of 28.3% of their body weight over a year and a half, and more than 45% of participants lost at least 30%, a level of efficacy the company said approaches results seen with bariatric surgery
Researchers with less weight to lose may not need the full 2.4 mg dose
However, the small number of people included in the study makes it difficult to generalize
Wegovy has been approved for weight loss, along with diet and exercise, for individuals aged 12 years and above with obesity or some overweight adults with weight-related medical problems
Sleep optimization strategies: Target 7-9 hours in a dark, cool room (65-68F) Avoid blue light 90 minutes before bed Consistent sleep/wake schedule, including weekends Limit alcohol it severely disrupts REM sleep and glucose regulation Cortisol and GLP-1 Resistance Chronic stress elevates cortisol, which has a bidirectional negative relationship with GLP-1